MASHINIi

Madrigal Pharmaceuticals, Inc..

MDGL.US | Research and experimental development on natural sciences and engineering

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for non-alcoholic steatohepatitis (NASH), a serious liver disease. Their primary focus is the development and potential commercialization of resmetirom, a thyroid hormone recept...Show More

Ethical Profile

Mixed.

Madrigal Pharmaceuticals is recognized for developing Rezdiffra, the first FDA-approved treatment for MASH, a serious liver disease, directly advancing public health. Environmentally, the company aims for a 15% energy efficiency reduction by 2025 and invests $1.2 million annually in carbon offsets. However, its DitchCarbon score of 25 is reportedly below the industry average of 33, suggesting room for improvement in planet-friendly practices. Total 2024 carbon emissions were 3,425 metric tons CO2 equivalent. As a pharmaceutical firm, it likely conducts animal testing in drug development. Many other ethical areas lack sufficient public data for a comprehensive assessment.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-30
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products-20
-100100

Better Health for All

0

No relevant evidence was found in the provided articles to assess Madrigal Pharmaceuticals, Inc. against the 'Better Health for All' ethical value. All articles either resulted in 404 errors or explicitly stated they contained no data specific to MDGL.US or this value.

1

Fair Money & Economic Opportunity

0

Madrigal Pharmaceuticals is a biopharmaceutical company focused on research, development, and clinical trials for therapeutics. Its core business does not involve lending, insuring, moving, or storing money, which are the activities evaluated under the 'Fair Money & Economic Opportunity' value. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its business model.

1
While the company offers patient assistance programs for drug access,
2
these are distinct from community finance or profit-sharing with underserved communities in the financial sense.

Fair Pay & Worker Respect

0

No evidence available to assess Madrigal Pharmaceuticals, Inc. on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

No evidence available to assess Madrigal Pharmaceuticals, Inc. on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

No specific, quantitative evidence was found across the provided articles to assess Madrigal Pharmaceuticals, Inc. against any of the 'Honest & Fair Business' KPIs. While an SEC settlement was mentioned, no specific financial value or terms were detailed, preventing scoring for regulatory fines.

1

Kind to Animals

0

No evidence available to assess Madrigal Pharmaceuticals, Inc. on Kind to Animals.

No War, No Weapons

0

Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing therapeutics for liver disease. The company is explicitly stated as not involved in military contracting, controversial weapons, or small arms.

1
Its core business does not involve defense or arms-related activities, dual-use technology, or military-focused AI.
2
Therefore, there is no defense business for the board to oversee, no ethical red lines related to weapons are needed, and no peace technology investment ratio is applicable in the context of military technology.

Planet-Friendly Business

-30

Madrigal Pharmaceuticals has a waste management target of 75% recycling.

1
The company reported 97% compliance with EPA environmental guidelines and no specific regulatory actions, violations, fines, or compliance issues.
2
It conducted 14 environmental impact studies in 2024, with an average assessment duration of 6.2 months.
3

Respect for Cultures & Communities

0

No evidence available to assess Madrigal Pharmaceuticals, Inc. on Respect for Cultures & Communities.

Safe & Smart Tech

0

No evidence available to assess Madrigal Pharmaceuticals, Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

-20

Madrigal Pharmaceuticals has no mentioned regulatory actions, violations, fines, or compliance issues related to waste disposal.

1
However, no data is provided regarding waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, material efficiency, packaging-to-product ratios, waste reduction targets, supplier waste requirements, or customer waste education.
2

Own Madrigal Pharmaceuticals, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.